Marcelo C. Pasquini, MD

Publications

• Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation.

  (Kean LS, Burns LJ, Kou TD, Kapikian R, Lozenski K, Langston A, Horan JT, Watkins B, Qayed M, Bratrude B, Betz K, Tang XY, Zhang MJ, Connolly SE, Polinsky M, Gavin B, Gomez-Caminero A, Pasquini MC.) Blood. 2024 Oct 24;144(17):1834-1845 PMID: 39028876 PMCID: PMC11530361 SCOPUS ID: 2-s2.0-85202515431 07/19/2024

• Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors.

  (Atsuta Y, Baldomero H, Neumann D, Sureda A, DeVos JD, Iida M, Karduss A, Purtill D, Elhaddad AM, Bazuaye NG, Bonfim C, De la Camara R, Chaudhri NA, Ciceri F, Correa C, Frutos C, Galeano S, Garderet L, Gonzalez-Ramella O, Greco R, Hamad N, Hazenberg MD, Horowitz MM, Kalwak K, Ko BS, Kodera Y, Koh MB, Liu K, McLornan DP, Moon JH, Neven B, Okamoto S, Pasquini MC, Passweg JR, Paulson K, Rondelli D, Ruggeri A, Seber A, Snowden JA, Srivastava A, Szer J, Weisdorf D, Worel N, Greinix H, Saber W, Aljurf M, Niederwieser D.) Haematologica. 2024 Oct 01;109(10):3282-3294 PMID: 38721749 PMCID: PMC11443380 SCOPUS ID: 2-s2.0-85199142319 05/09/2024

• Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research Registry.

  (Cusatis R, Litovich C, Feng Z, Allbee-Johnson M, Kapfhammer M, Mattila D, Akinola I, Phelan R, Broglie L, Auletta JJ, Steinert P, Bolon YT, Akhtar O, Bloomquist J, Chen M, Devine SM, Bupp C, Hamadani M, Hengen M, Jaglowski S, Kaur M, Kuxhausen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Rizzo D, Saber W, Spellman SR, Stefanski HE, Tuschl E, Yusuf R, Zhan K, Flynn KE, Shaw BE.) Transplant Cell Ther. 2024 Sep;30(9):917.e1-917.e12 PMID: 38944153 SCOPUS ID: 2-s2.0-85199289175 06/30/2024

• Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention.

  (Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, Akhtar O, D'Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, Hamadani M.) Blood Adv. 2024 Aug 27;8(16):4320-4329 PMID: 38889435 PMCID: PMC11372811 SCOPUS ID: 2-s2.0-85203009004 06/18/2024

• Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.

  (Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, Zhang Y, Brunstein C, Efebera Y, Geller N, Giralt S, Hari P, Horowitz MM, Koreth J, Krishnan A, Landau H, Somlo G, Shah N, Stadtmauer E, Vogl DT, Vesole DH, McCarthy PL, Hahn T.) J Clin Oncol. 2024 Aug 10;42(23):2757-2768 PMID: 38701390 SCOPUS ID: 2-s2.0-85201029574 05/03/2024

• Don't keep me waiting: estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes.

  (Vadgama S, Pasquini MC, Maziarz RT, Hu ZH, Ray M, Smith H, Bullement A, Edmondson-Jones M, Sullivan W, Cartron G.) Blood Adv. 2024 Jul 09;8(13):3519-3527 PMID: 38662645 PMCID: PMC11261112 SCOPUS ID: 2-s2.0-85198138125 04/25/2024

• Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.

  (Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, Perales MA, Munoz J, Fingrut WB, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza AS, Abid MB, Hong S, Majhail NS, Kharfan-Dabaja MA, Khurana A, Badar T, Lin Y, Bennani NN, Herr MM, Hu ZH, Wang HL, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini MC.) Blood. 2024 Jun 27;143(26):2722-2734 PMID: 38635762 PMCID: PMC11251200 SCOPUS ID: 2-s2.0-85193847404 04/18/2024

• Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.

  (Gagelmann N, Bishop M, Ayuk F, Bethge W, Glass B, Sureda A, Pasquini MC, Kröger N.) Transplant Cell Ther. 2024 Jun;30(6):584.e1-584.e13 PMID: 38281590 SCOPUS ID: 2-s2.0-85187506193 01/29/2024

• Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.

  (Lunning MA, Wang HL, Hu ZH, Locke FL, Siddiqi T, Jacobson CA, Ahmed S, Miklos DB, Lin Y, Hill BT, Ghobadi A, Neelapu SS, Westin J, Dieyi C, Field P, Miao H, Shahani SA, Patel A, Spooner C, Fu C, Muramoto D, Xu H, Pasquini MC.) Am J Hematol. 2024 May;99(5):880-889 PMID: 38504387 SCOPUS ID: 2-s2.0-85188568576 03/20/2024

• Symptom clusters and their impact on quality of life in multiple myeloma survivors: Secondary analysis of BMT CTN 0702 trial.

  (Brazauskas R, Flynn K, Krishnan A, Landau H, Giralt S, Pasquini MC, Stadtmauer EA, D'Souza A.) Br J Haematol. 2024 Apr;204(4):1429-1438 PMID: 38348544 PMCID: PMC11006567 SCOPUS ID: 2-s2.0-85185482209 02/13/2024

• Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.

  (Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, Horwitz EM, Grupp SA, Maus MV, Locke FL, Ciceri F, Ruggeri A, Snowden J, Heslop HE, Mackall CL, June CH, Sureda AM, Perales MA.) Nat Med. 2024 Feb;30(2):338-341 PMID: 38195751 SCOPUS ID: 2-s2.0-85181956361 01/10/2024

• The role of registries in hematological disorders

  (Baldomero H, Neumann D, Hamad N, Atsuta Y, Sureda A, Iida M, Karduss A, Elhaddad AM, Bazuaye NG, Bonfim C, Camara Rdl, Chaudhri NA, Ciceri F, Correa C, Frutos C, Galeano S, Garderet L, Greco R, Jaimovich G, Kodera Y, Koh MB, Liu K, Ljungman P, McLornan DP, Nair G, Okamoto S, Pasquini MC, Passweg J, Paulson K, Ruggeri A, Seber A, Snowden JA, Srivastava A, Worel N, Saber W, Rondelli D, Aljurf M, Niederwieser D.) Best Practice and Research: Clinical Haematology. June 2024;37(2) SCOPUS ID: 2-s2.0-85199185606 06/01/2024